Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

84.14 +2.58 (+3.16%)
Streaming Delayed Price Updated: 10:00 AM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
3 Unpopular Stocks We Steer Clear Of
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum ↗
Via Chartmill
News headline image
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
3 Reasons to Sell CORT and 1 Stock to Buy Instead
Corcept’s stock price has taken a beating over the past six months, shedding 35% of its value and falling to $50.98 per share. This was partly driven by its ... 
Via StockStory
News headline image
3 High-Flying Stocks We Think Twice About
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
News headline image
Corcept (CORT) Q1 2026 Earnings Transcript ↗
Corcept (CORT) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Corcept (CORT) Q4 2025 Earnings Transcript ↗
Corcept (CORT) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Corcept (CORT) Q1 2025 Earnings Transcript ↗
Corcept (CORT) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Corcept (CORT) Q2 2025 Earnings Transcript ↗
Corcept (CORT) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million... 
Via StockStory
News headline image
Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million... 
Via StockStory
News headline image
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Earnings: What To Look For From CORT
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Thursday after market hours. Here’s what to look for. Corcept m... 
Via StockStory
Topics Artificial Intelligence
News headline image
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
CORCEPT DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
1 Cash-Producing Stock for Long-Term Investors and 2 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21st
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener... 
Via StockStory
Topics Economy
News headline image
Deadline Soon: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
3 Overrated Stocks That Concern Us
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a... 
Via StockStory
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.